View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 2, 2021updated 11 Jul 2022 2:19pm

Janssen reports encouraging data from psoriatic arthritis therapy trial

In the trial, subjects in the groups who received Tremfya had reduced radiographic progression rates at week 100.

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported positive complete efficacy and safety data from the Phase III clinical trial of selective Interleukin (IL)-23 inhibitor therapy, Tremfya (guselkumab), to treat active psoriatic arthritis (PsA).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A fully human monoclonal antibody, Tremfya acts on the p19 subunit of IL-23, which is associated with the pathogenesis of inflammatory diseases.

The double-blind, randomised, multicentre Phase III DISCOVER–2 trial assessed the efficacy and safety of subcutaneous dose of Tremfya in biologic-naïve subjects with active PsA.

It enrolled 739 subjects who received the treatment and were followed up for nearly two years.

Among the Tremfya-treated subjects with an ACR20/50/70 response at week 52, 91% and 87% received the drug every four weeks (q4w) and every eight weeks (q8w), respectively, and sustained an ACR20 response at week 100.

An ACR50 response was maintained in nearly 83% of q4w and 79% of q8w subjects while 72% and 80% had an ACR70 response.

From week 0-100, reduced rates of radiographic progression were reported in both dosing regimens of the antibody.

At week 100, the rates of enthesitis and dactylitis resolution demonstrated that improvement in the signs and symptoms of arthritis were durable for two years.

In addition, 62% and 55% of the subjects in the q4w and q8w arms, respectively, attained a complete skin clearance with an Investigator Global Assessment (IGA) score of zero.

Approximately 76% and 72% in the q4w and q8w arms attained an IGA score of zero or one.

Furthermore, 38% and 40% of the subjects who received Tremfya q4w and q8w, respectively, attained minimal disease activity criteria at week 100.

The data from the trial is in line with the already reported safety profile of Tremfya.

Janssen Research and Development vice-president and rheumatology disease area leader Alyssa Johnsen said: “The response rates in the DISCOVER-2 trial demonstrate the ability of Tremfya to improve the signs and symptoms of psoriatic arthritis for people who live with the challenges of this disease.

“Psoriatic arthritis is a chronic disease, so patients need treatment options with durable efficacy and an established safety profile. We are proud to deliver the first two-year results for a selective IL-23 inhibitor therapy in PsA.”

In October 2020, Janssen reported that open-label extension data from Phase III VOYAGE 1 study of Tremfya demonstrated increased rates of skin clearance in plaque psoriasis patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena